Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Pfizer

Moderna Inc has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically designed to target the omicron coronavirus variant.

After Pfizer, Moderna Kickstarts Omicron-Targeted COVID-19 Vaccine Trial

Moderna CEO Stéphane Bancel previously projected the Omicron-specific vaccine booster to be available as early as this fall.

Moderna began a clinical trial testing an Omicron-specific vaccine booster shot in adults

Phase 2 study of Omicron-specific booster candidate ( mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including participants who received the two-dose primary series and a 50 µg booster dose of mRNA-1273 Omicron neutralization six months after the third 50 µg dose of mRNA-1273 declined, but remained detectable in all participants CAMBRIDGE, MA / ACCESSWIRE / January 26, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 2 study of the Company's Omicron-specific booster candidate (mRNA-1273.529). Additionally, Moderna announced the publication of neutralizing antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine.

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant

The first participant in the trial has already received a dose of the omicron-specific booster shot, according to Moderna.

Moderna starts clinical trial of booster shot targeting omicron Covid variant

BioNTech SE

Novavax

The CDC is making a push for fourth shots for the immuno-compromised.

Why Coronavirus Vaccine Stocks Topped the Market Today

Moderna Inc (NASDAQ:MRNA) shares are trading higher by 7.2% at $163.54 Wednesday afternoon after Deutsche Bank upgraded the stock from Sell to Hold and announced a $175 price target. Shares of vaccine companies were otherwise trading lower during Tuesday's session.

Why Moderna Shares Are Rising

Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.

Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?

Shares of Moderna Inc. MRNA, -3.03% bounced 4.3% in premarket trading, putting them on track to snap a record eight-day losing streak, after Deutsche Bank analyst Emmanuel Papadakis said investors can stop selling after the recent precipitous decline. The COVID-19 vaccine provider's stock has plunged 31.6% during its losing streak, which is the longest since the biotechnology company went public in December 2018, and has plummeted 68.5% since its Aug. 9, 2021 post-pandemic peak of $484.47.

Moderna stock set to snap record losing streak after Deutsche Bank says it's time to stop selling

Moderna stock (NASDAQ: MRNA) has lost almost a third of its value thus far in 2022 and currently trades at about $160 per share. The sell-off is driven by two broad factors.

Moderna Stock Falls To $160. Should You Buy, Sell Or Hold?

First Majestic Silver

Shopify

If these aggressive price targets are accurate, two of these growth stocks could triple over the next 12 months.

3 Fast-Growing Stocks With 93% to 222% Upside, According to Wall Street

Enphase Energy

Netflix

If you are still in profit, dump Moderna stock now and wait for re-entry at a much lower zone.

Worst Performing S&P 500 Stocks You Should Dump Immediately

Moderna, Inc. (NASDAQ:MRNA), one of the two major providers of the Covid-19 inoculations that rallied during the pandemic, has lost about 40% of its value since the beginning of January, putting it on track for its worst monthly loss ever. Approximately 807 million doses of the Moderna COVID-19 vaccine were shipped by the company in […] La notizia Moderna stock continues to rout; as the fight between bulls and bears continue era stato segnalata su Invezz.

Moderna stock continues to rout; as the fight between bulls and bears continue

Applied Materials

NVIDIA

Atlassian

Xilinx

Tech stocks got off to a poor start again Tuesday morning. The Nasdaq was down about 1.4% in the first few minutes of trading.

Tuesday Morning's 5 Tech Stock Movers

The bullish case for owning COVID-19 vaccine makers is weakening as much of the world throws in the towel on trying to curb the spread of the coronavirus.

Why Vaccine Stocks Like Moderna and Novavax Tumbled (Again) Today

On a wild Monday, the broad U.S. stock market turned green in the last few minutes of trading, recovering from big declines early in the day.

Deep Dive: These stocks in the S&P 500 had price swings of 10% or more Monday

Etsy

The S&P 500's worst performers have all lost more than 30% this year.

Moderna, Netflix, and Etsy Are the S&P 500's Worst Performing Stocks This Year

Spikevax sales may not be able to carry the stock upward any further.

What's Next For Moderna Stock?

AstraZeneca

Vertex Pharmaceuticals

All of them have tremendous growth prospects.

3 Unstoppable Biotech Stocks to Buy Right Now

The COVID-19 vaccine maker is jumping into CAR-M technology with its deal with Carisma Therapeutics.

Moderna Is Betting on a New Way to Fight Cancer

It's important to look at the big picture.

The Worst Mistake Moderna Investors Can Make in 2022

Shares of Moderna Inc. MRNA, -2.51% slumped 2.3% toward an eight-month low in morning trading Friday, and have tumbled 26.5% amid a six-day losing streak, enough for formerly bearish BofA Securities analyst Geoff Meacham to say investors should stop selling the biotechnology company. Meacham raised his rating to neutral from underperform, and lifted his stock price target to $180 from $135.

Moderna's stock has tumbled enough for a long-time bear to say stop selling

Moderna was last year's third best-performing stock in the S&P—it's now this year's worst.

Moderna Stock Crash Intensifies: Losses Top $130 Billion After Scientists Find Covid Boosters Aren't Halting Omicron Infections

Ocugen, Inc.

Several factors are dragging down these vaccine stocks.

Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week

The huge new CDC dataset backs up what other studies have found, that Moderna is edging out Pfizer and J&J is offering less protection against COVID.

News for Moderna Stock (MRNA)